US Bancorp
GPCR icon

US Bancorp’s Structure Therapeutics GPCR Stock Holding History

US Bancorp’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$482 – 4242
2026
Q1 		$482 Buy
+10
New +$684 ﹤0.01% 4010
2025
Q3 		– Sell
-13
Closed -$270 – 4127
2025
Q2 		$270 Hold
13
– – ﹤0.01% 4054
2025
Q1 		$225 Sell
13
-88
-87% -$2.16K ﹤0.01% 4089
2024
Q4 		$2.74K Buy
101
+88
+677% +$3.12K ﹤0.01% 3798
2024
Q3 		$571 Sell
13
-1,499
-99% -$58K ﹤0.01% 3940
2024
Q2 		$59.4K Buy
+1,512
New +$62.1K ﹤0.01% 2579

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

US Bancorp's GPCR Position: Q2 2026 in Review

US Bancorp sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 10 shares — an estimated $482 sold.

US Bancorp first reported a position in GPCR in Q2 2024 and held it in 6 quarters. The position peaked at $59.4K in Q2 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • US Bancorp reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • US Bancorp sold 10 Structure Therapeutics shares in Q2 2026, an estimated $482.
  • US Bancorp first reported a position in Structure Therapeutics in Q2 2024 and held it in 6 quarters.
  • US Bancorp's Structure Therapeutics position peaked at $59.4K in Q2 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.